Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 4.3%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) dropped 4.3% on Wednesday . The stock traded as low as $25.14 and last traded at $25.15. Approximately 42,987 shares were traded during trading, a decline of 92% from the average daily volume of 513,474 shares. The stock had previously closed at $26.27.

Analysts Set New Price Targets

ARCT has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. Canaccord Genuity Group lowered their target price on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a report on Friday, May 10th. Finally, William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.86.

Arcturus Therapeutics Stock Performance

The firm has a market capitalization of $658.44 million, a PE ratio of -6.25 and a beta of 2.76. The stock has a fifty day moving average price of $30.22 and a 200-day moving average price of $32.54.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.17) by $0.17. The company had revenue of $38.01 million for the quarter, compared to analyst estimates of $22.12 million. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. Research analysts expect that Arcturus Therapeutics Holdings Inc. will post -4.39 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Pad Chivukula sold 26,000 shares of Arcturus Therapeutics stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the completion of the sale, the chief operating officer now directly owns 447,448 shares in the company, valued at $17,902,394.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 13.80% of the company’s stock.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently bought and sold shares of ARCT. SummerHaven Investment Management LLC lifted its stake in Arcturus Therapeutics by 1.7% during the 4th quarter. SummerHaven Investment Management LLC now owns 22,704 shares of the biotechnology company’s stock valued at $716,000 after acquiring an additional 378 shares during the period. CANADA LIFE ASSURANCE Co lifted its position in Arcturus Therapeutics by 10.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 428 shares during the period. Formidable Asset Management LLC boosted its holdings in Arcturus Therapeutics by 3.3% in the fourth quarter. Formidable Asset Management LLC now owns 15,550 shares of the biotechnology company’s stock valued at $490,000 after purchasing an additional 500 shares during the last quarter. BNP Paribas Financial Markets grew its position in Arcturus Therapeutics by 3.0% during the 4th quarter. BNP Paribas Financial Markets now owns 23,259 shares of the biotechnology company’s stock worth $733,000 after purchasing an additional 682 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Arcturus Therapeutics by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock valued at $1,078,000 after buying an additional 778 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.